This study is a randomised, placebo-controlled study of the effect of treatment with the
HMG-CoA reductase inhibitor, pravastatin, in HIV-infected, protease inhibitor treated
patients with high serum cholesterol. We hypothesise that pravastatin will result in greater
reductions in cholesterol than placebo when used in conjunction with appropriate dietary
advice.
Phase:
Phase 4
Details
Lead Sponsor:
Kirby Institute
Collaborators:
Garvan Institute of Medical Research National Heart, Lung, and Blood Institute (NHLBI) St Vincent's Hospital, Sydney The University of New South Wales